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1. Introduction 
Secretion of prolactin from the anterior pituitary 
gland is dependent on the presence of extracellular 
calcium. Manipulations which increase cytosolic al- 
cium, such as incubation of pituitary cells with iono- 
phores or with high potassium, stimulate hormone 
release [1-4]. Spontaneous depolarising action 
potentials have been recorded in both normal and 
tumour pituitary cells and, in general, thyrotropin- 
releasing hormone (TRIt) increases and dopamine 
decreases these calcium-dependent ac ion potentials 
[5-9]. In addition, agents which inhibit calcium flux 
also inhibit pituitary hormone secretion [1,4]. How- 
ever, the precise role ofintracellutar calcium in the 
secretory process is unknown. 
Many of the effects of calcium in tissues may be 
mediated through its interaction with the calcium- 
dependent regulator, calmodulin [ 10]. Calmodulin, a
protein first discovered as a heat-stable activator of 
cyclic nucleotide phosphodiesterase [ 11], was later 
found to influence the activity of several other intra- 
cellular enzymes [ 12-14]. A number of neuroleptic 
drugs have been found to bind to calmodulin and to 
inhibit its action [15]. Among the most potent of 
these drugs are the phenothiazine tranquillizers [ 15]. 
In preliminary studies, we observed that trifluoper- 
azine inhibited prolactin secretion from isolated 
pituitary cells [ 16]. Therefore, we have investigated 
the hypothesis that calmodulin has a role in prolactin 
secretion by studying the dose-dependence of the 
effects of two potent calmodulin inhibitors, trifluo- 
perazine and prochlorperazine, on prolactin secretion 
in vitro. We have also investigated the effects of the 
sulphoxide derivatives of these drugs. Here, we report 
that both trifluoperazine and prochlorperazine i hibit 
prolactin secretion from rat anterior pituitary cells 
in vitro, but that the sulphoxide analogues have no 
such inhibitory effects. 
2. Materials and methods 
The culture medium (Ham's F10) was from Flow 
Labs (Irvine); the foetal calf serum, penicillin and 
streptomycin were from Gibco-Europe (Paisley). The 
trypsin was obtained from Difco Labs (West Molesey, 
Surrey) and the soya bean trypsin inhibitor was from 
Sigma (London) Chemical Co. (Poole, Dorset). Bovine 
serum albumin (fraction V) was from Armour Phar- 
maceuticals (Eastbourne, Sussex). TRH was a gift 
from Reckitt and Cotman Ltd. (Hull) and the pheno- 
thiazines were gifts from Smith, Kline and French 
Labs (Welwyn Garden City, Herts). All other chemi- 
cals were from BDH Chemicals (Poote, Dorset). 
Anterior pituitary cells were prepared from adult 
male Sprague-Dawley rats by sequential incubation in 
trypsin (0.25%; 45 min), then soya bean trypsin inhib- 
itor (0.25%; 10 min) following which they were iso- 
lated by mechanical dispersion [ 17]. The cells were 
distributed in multiwell culture plates (70 000 cells/ 
well) in Ham's F10 medium (with 10% foetal calf 
serum and 100 units/ml penicillin/streptomycin) a d
used in experiments 3 days later. The incubation 
medium was Krebs-Ringer bicarbonate (pit 7.6.) with 
0.5% bovine serum albumin and 0.2% glucose (KRB). 
After a 2 h preincubation i  KRB, the cells were 
washed with KRB, then incubated in 1 ml KRB con- 
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taining the secretagogues and drugs for 1 h at 37°C in 
an atmosphere of95% 02/5% CO2. The test substances 
were made up in KRB with the exception of trifluo- 
perazine sulphoxide, prochlorperazine and prochlor- 
perazine sulphoxide which were solubilized first in 
dimethylsulphoxide (DMSO). The final concentration 
of DMSO in KRB was 1%. Trifluoperazine was also 
dissolved first in DMSO in those experiments compar- 
ing the effects of all the phenothiazines and equivalent 
concentrations of DMSO were added to the appropriate 
controls. When increased K + concentrations were used, 
isotonicity was maintained by a compensating reduc- 
tion in the concentration f Na +. Prolactin released 
into the medium was measured in triplicate by radio- 
immunoassay using materials supplied by the National 
Pituitary Agency, NIAMDD, National Institutes of 
Health (Bethesda MD). Separation of the bound and 
free moieties was achieved by precipitation of the 
bound fraction with donkey anti-rabbit antiserum. 
Inter- and intra-assay variations were <8.5%. 
All the incubations were performed in triplicate 
within each experiment. The significances were 
assessed by analysis of variance. 
3. Results 
The effect of trifluoperazine on both basal and 
stimulated prolactin secretion in one experiment is 
shown in fig.1. The results of the separate xperiments 
have been pooled and are shown in table 1. (Data are 
expressed as percentage change since basal release was 
variable.) It is clear that trifluoperazine exerts a dose- 
dependent inhibition on basal prolactin secretion at 
Table 1 
Inhibition of prolactin secretion by trifluoperazine 
Trifluoperazine Basal TRH (n = 4) K + (n = 4) 
(uM) (n = 6) (10 ng/ml) (35 mM) 
0 t00 i00 100 
0.084 91.5- + 6.4 94.1 +_ 2.9 100.4-+ 8.1 
0.42 94.4-+ 6.3 105.8 -+ 7.6 97.9 -+ 3.9 
0.84 97.6 +- 9.0 99.6 _+ 10.5 94.8 +- 5.1 
4.2 83.9-+ 10.9 79.4 +_ 8.5 87.4 ± 7.5 
8.4 60.4 -+ 7.2 58.7 -+ 7.4 73.7 ± 4.6 
42 52.3 -+ 6.2 54.5 -+ 8.3 56.2-+ 2.3 
84 80.4 -+ 11.5 74.6 _+ 16.7 84.4 -+ 21.1 
Pooled data from separate experiments expressed as a per- 
centage of the value in the absence of trifluoperazine (mean _+ 
SEM) 
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Fig.1. The effect of trifluoperazine on basal (=) TRH-stim- 
ulated (o) and K+-stimulated (A)prolactin secretion, +P < 0.02, 
*P < 0.002 for inhibition relative to the control evels of 
secretion. Prolactin secretion was stimulated by TRH and 
K* (P < 0.002). 
>4.2/aM. This phenothiazine inhibited prolactin 
secretion in the presence and in the absence of TRH. 
Prolactin secretion stimulated by increased extracel- 
lular K + concentration was also inhibited by trifluo- 
perazine. The inhibitory effect appears to be less pro- 
nounced or even absent at 84/aM trifluoperazine, It 
is probable that the apparent tack of inhibition at 
84/aM is due to cytotoxicity since a high proportion 
of the cells incubated with this dose (but not lower 
concentrations) of trifluoperazine took up trypan 
blue. 
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Since the phenothiazine antipsychotics have been 
reported to have effects other than on calmodulin 
action, it was important to compare the effects of 
these phenothiazines with those of derivatives that 
are known (or suspected) to be less potent inhibitors 
of calmodulin action [ 15 ]. The results of these exper- 
iments are shown in fig.2, which depicts the effect of 
trifluoperazine, prochlorperazine and the sulphoxide 
derivatives on basal prolactin secretion. It is apparent 
that the sulphoxides were without inhibitory effect, 
in the dose range 0.084-84/aM, in the same experi- 
ments in which the parent compounds had profound 
inhibitory effects. Trifluoperazine sulphoxide isknown 
to be considerably ess potent as a calmodulin inhib- 
itor [18,19]. The cause of the slight stimutatory effect 
of the prochlorperazine sulphoxide is not yet known. 
4. Discussion 
Trifluoperazine, a phenothiazine tranquillizer, 
inhibited prolactin release from rat anterior pituitary 
cells in vitro. In this study, the maximal effect was 
observed at 42/aM with an EDso of--~6/aM (from 6 
expt). This latter value is similar to the dose required 
for half-maximal effects of trifluoperazine on inhibi- 
tion of calmodulin-activated phosphodiesterase [20] 
and on binding to calmodulin [15]. Trifluoperazine 
also inhibited prolactin secretion i  the presence of 
TRH and of high K ÷ concentration. Prochlorperazine, 
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Fig.2. (a) The effect of trifluoperazine ( ) and trifluoperazine sulphoxide (o) on basal prolactin secretion in a representative 
experiment. (b) The effect of prochlorperazine (*) and prochlorperazine sulphoxide (~) on basal prolactin secretion in the same 
experiment. *P < 0.01 for inhibition relative to the control evels of secretion. 
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which has also been shown to bind to calmodulin and 
inhibit its action, was also effective in inhibiting pro- 
lactin secretion. The EDso for this drug was ~5/aM, 
which again is similar to its known binding constant 
with calrnodulin and the ICso for the inhibition of 
calmodulin-activated phosphodiesterase [19]. These 
results suggest hat the drugs may be interacting with 
calmodulin within the cell and that this interaction in 
some way leads to inhibition of the secretory process. 
However, these drugs may also have calmodulin-inde- 
pendent actions, such as a local anaesthetic-like action 
on Na ÷ conductance [21 ] and interference with cate- 
cholamine binding to cells [22]. Nevertheless, the 
close relationship between the potencies of these 
drugs in inhibiting prolactin secretion and in affecting 
calmodulin action argues in favour of a calmodulin- 
dependent effect. This argument is strengthened by 
the finding that trifluoperazine sulphoxide did not 
influence hormone secretion. This derivative has been 
shown to have a lower (at least 1/30th) potency on 
inhibition of calmodulin-activated phosphodiesterase 
[18]. Moreover, the sulphoxide analogue of prochlor- 
perazine, which is also less potent in inhibiting cal- 
modulin-activated phosphodiesterase (unpublished) 
was also ineffective in inhibiting prolactin secretion. 
Calmodulin may also be involved in insulin secre- 
tion [ 19,23,24], vasopressin-stimulated water flow 
[25], intestinal ion secretion [26,27] and stimulated 
thyrotropin secretion [28], in other cellular systems. 
However, this is the first report of a possible role for 
calmodulin in basal and stimulated prolactin secretion. 
Since calmodulin activates cyclic nucleotide phos- 
phodiesterase and calcium-dependent phosphorylation 
mechanisms it will be interesting to determine whether 
phenothiazines influence cyclic nucleotide (especially 
cyclic GMP) accumulation i pituitary cells and 
whether protein phosphorylation is affected. Such 
studies are now in progress in our laboratory. 
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